reMYND, Roche deal

The partners will develop two of reMYND's preclinical programs to treat Parkinson's disease and Alzheimer's disease. The programs consist of small molecules against undisclosed targets that prevent alpha-synuclein ( SNCA) neurotoxicity and microtubule-associated protein tau (MAPT; tau; FTDP-17) neurotoxicity to treat PD and AD, respectively. The deal includes lead compounds ReS9-S for PD and ReS19-T for AD, as well as backup compounds. ...